Quest Diagnostics (DGX) Cash from Financing Activities (2009 - 2026)

Quest Diagnostics (DGX) has 18 years of Cash from Financing Activities data on file, last reported at -$152.0 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 72.91% year-over-year to -$152.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$979.0 million (down 244.82% YoY) and the FY2025 annual result came in at -$1.4 billion, down 228.04% from the prior year.
• Cash from Financing Activities rose to -$152.0 million in Q1 2026 per DGX's latest filing, from -$287.0 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $1.8 billion in Q3 2024, with the low at -$561.0 million in Q1 2025.
• Average Cash from Financing Activities over 5 years is -$119.3 million, with a median of -$242.0 million recorded in 2022.
• Year-over-year, Cash from Financing Activities sank 1147.37% in 2022 and soared 2232.53% in 2024.
• Quest Diagnostics' Cash from Financing Activities stood at -$545.0 million in 2022, then jumped by 123.85% to $130.0 million in 2023, then plunged by 230.77% to -$170.0 million in 2024, then tumbled by 68.82% to -$287.0 million in 2025, then jumped by 47.04% to -$152.0 million in 2026.
• Business Quant data shows DGX's Cash from Financing Activities at -$152.0 million in Q1 2026, -$287.0 million in Q4 2025, and -$247.0 million in Q3 2025.